Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 May 2:2019:2532518.
doi: 10.1155/2019/2532518. eCollection 2019.

Immune Exclusion Is Frequent in Small-Cell Carcinoma of the Bladder

Affiliations

Immune Exclusion Is Frequent in Small-Cell Carcinoma of the Bladder

Tim Mandelkow et al. Dis Markers. .

Abstract

Small-cell cancer of the urinary bladder is a rare but highly aggressive disease. It is currently unclear whether immune checkpoint therapies that have been approved for urothelial carcinomas will also be efficient in small-cell carcinomas. In this study, we analyzed potential predictors of response including PD-L1 expression and the quantity and location of tumor-infiltrating lymphocytes (TILs) in 12 small-cell and 69 "classical" urothelial cancers by immunohistochemistry. The analysis revealed that small-cell carcinomas were characterized by the virtual absence of PD-L1 expression and an "immune-excluded" phenotype with only a few TILs in the center of the tumor (CT). In small-cell carcinomas, the average immune cell density in the CT (CD3: 159 ± 206, CD8: 87 ± 169 cells/mm2) was more than 3 times lower than that in the urothelial carcinomas (CD3: 625 ± 800, p < 0.001; CD8: 362 ± 626 cells/mm2, p = 0.004) while there was no significant difference in the immune cell density at the invasive margin (IM) (small-cell carcinomas CD3: 899 ± 733, CD8: 404 ± 433 cells/mm2; urothelial carcinomas CD3: 1167 ± 1206, p = 0.31; CD8: 582 ± 864 cells/mm2, p = 0.27). Positive PD-L1 staining was found in 39% of urothelial cancers, but in only 8% of small-cell bladder cancer cases (p = 0.04). Concordant with these data, a sharp decrease of PD-L1 positivity from >80% to 0% positive cells and of TILS in the CT from 466-1063 CD3-positive cells/mm2 to 50-109 CD3-positive cells/mm2 was observed in two cancers with clear-cut progression from "classical" urothelial to small-cell carcinoma. In conclusion, these data demonstrate that small-cell bladder cancer commonly exhibits an immune-excluded phenotype.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Representative pictures of CD3 staining (brown color) in (a, b) two cases of small-cell and (c, d) two cases of urothelial carcinoma of the bladder. Panels (a, c) show examples of the immune-desert phenotype and (b, d) examples of the immune-excluded phenotype. Arrowheads indicate the invasive margin. Asterisks label the center of the tumor, shown also in the insets at 400x magnification.
Figure 2
Figure 2
Comparison of CD3-, CD8-, and PD-1-positive cell densities at the invasive margin (IM) and center of the tumor (CT) between 12 small-cell carcinomas (SCCB) and 69 urothelial carcinomas of the bladder (UCB).
Figure 3
Figure 3
CD3 and PD-L1 staining of a sample from patient 4 that contained adjacent areas of small-cell and urothelial carcinoma of the bladder. Note the invasive margin (arrowhead) and the center of the tumor (asterisks). Insets show 400x magnification of the tumor bulk.

References

    1. Choong N. W., Quevedo J. F., Kaur J. S. Small cell carcinoma of the urinary bladder. The Mayo Clinic experience. Cancer. 2005;103(6):1172–1178. doi: 10.1002/cncr.20903. - DOI - PubMed
    1. Ismaili N. A rare bladder cancer--small cell carcinoma: review and update. Orphanet Journal of Rare Diseases. 2011;6(1):p. 75. doi: 10.1186/1750-1172-6-75. - DOI - PMC - PubMed
    1. Cheng L., Pan C. X., Yang X. J., et al. Small cell carcinoma of the urinary bladder: a clinicopathologic analysis of 64 patients. Cancer. 2004;101(5):957–962. doi: 10.1002/cncr.20456. - DOI - PubMed
    1. Hsu F. S., Su C. H., Huang K. H. A comprehensive review of US FDA-approved immune checkpoint inhibitors in urothelial carcinoma. Journal of Immunology Research. 2017;2017:9. doi: 10.1155/2017/6940546.6940546 - DOI - PMC - PubMed
    1. Wilde L., Ali S. M., Solomides C. C., Ross J. S., Trabulsi E., Hoffman-Censits J. Response to pembrolizumab in a patient with chemotherapy refractory bladder cancer with small cell variant histology: a case report and review of the literature. Clinical Genitourinary Cancer. 2017;15(3):e521–e524. doi: 10.1016/j.clgc.2016.12.012. - DOI - PubMed

MeSH terms